Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Current Leases (2019 - 2025)

Collegium Pharmaceutical (COLL) has 7 years of Current Leases data on record, last reported at $1.4 million in Q3 2025.

  • For Q3 2025, Current Leases rose 7.95% year-over-year to $1.4 million; the TTM value through Sep 2025 reached $1.4 million, up 7.95%, while the annual FY2024 figure was $1.3 million, 28.64% up from the prior year.
  • Current Leases reached $1.4 million in Q3 2025 per COLL's latest filing, up from $1.3 million in the prior quarter.
  • Across five years, Current Leases topped out at $1.4 million in Q3 2025 and bottomed at $750000.0 in Q1 2021.
  • Average Current Leases over 5 years is $1.1 million, with a median of $1.0 million recorded in 2023.
  • Peak YoY movement for Current Leases: soared 57.07% in 2022, then fell 19.82% in 2023.
  • A 5-year view of Current Leases shows it stood at $814000.0 in 2021, then skyrocketed by 36.61% to $1.1 million in 2022, then fell by 11.15% to $988000.0 in 2023, then increased by 28.64% to $1.3 million in 2024, then increased by 7.95% to $1.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Leases were $1.4 million in Q3 2025, $1.3 million in Q2 2025, and $1.3 million in Q1 2025.